168 related articles for article (PubMed ID: 16858944)
1. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
2. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
3. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
4. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
5. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
6. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment.
Eftekhari M; Asadollahi A; Beiki D; Izadyar S; Gholamrezanezhad A; Assadi M; Fard-Esfahani A; Fallahi B; Takavar A; Saghari M
Hell J Nucl Med; 2008; 11(3):160-3. PubMed ID: 19081859
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
8. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
9. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in hypoparathyroid women on LT4 suppressive therapy. Effect of calcium and 1,25(OH)2 vitamin D3 treatment.
Hawkins F; Escobar-Jiménez F; Jódar E; Campos MM; López Alvarez MB; Martínez Díaz-Guerra G
J Musculoskelet Neuronal Interact; 2003 Mar; 3(1):71-6. PubMed ID: 15758368
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: a prospective study.
Lumachi F; Camozzi V; Ermani M; DE Lotto F; Luisetto G
Ann N Y Acad Sci; 2007 Nov; 1117():357-61. PubMed ID: 17646261
[TBL] [Abstract][Full Text] [Related]
13. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
Diamond T; Nery L; Hales I
J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
15. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women.
Boonya-Ussadorn T; Punkaew B; Sriassawaamorn N
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S1-5. PubMed ID: 21284134
[TBL] [Abstract][Full Text] [Related]
17. Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus.
Uaratanawong S; Deesomchok U; Hiransuttikul N; Uaratanawong S
J Med Assoc Thai; 2004 Nov; 87(11):1374-9. PubMed ID: 15825716
[TBL] [Abstract][Full Text] [Related]
18. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
20. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]